• About us
• Contact

Advertisement

Organisation › Details

Nanna Therapeutics Ltd.

Nanna Therapeutics Limited is developing breakthrough medicines for the treatment of age-related diseases, focusing first on those linked to mitochondrial dysfunction, including MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes) syndrome, Kearns-Sayrem syndrome and Parkinson’s disease. To this end, Nanna Therapeutics Limited has built unique, game-changing platforms to improve drug discovery by its ability to create and screen millions of biological or biologically-inspired novel compounds in disease-relevant settings. This provides a paradigm shift in the efficiency and quality of drug discovery with the goal to improving clinical success. *

 

	Start	2018-08-14 renamed
	Group	Astellas (Group)
	Predecessor	Bactevo Ltd.
	Industry	Totally Integrated Medicines Engine (TIME)
	Industry 2	drug discovery
	Person	Williams, David (Nanna Therapeutics 202004 CEO before Discuva)
	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	Rosemary Lane The Merryfield Centre
	City	CB1 3LQ Cambridge
	Tel	+44-1223-247000
		Address record changed: 2024-01-05
Basic data	Employees	n. a.
		* Document for »About Section«: Nanna Therapeutics Ltd.. (4/21/20). "Press Release: Astellas Announces Acquisition of Nanna". Tokyo & Cambridge.
		Record changed: 2024-02-20

Advertisement

More documents for Astellas (Group)

• [1] Mogrify Ltd.. (10/2/23). "Press Release: Mogrify Extends Series A Financing to $46 Million USD". Cambridge....
• [2] Mogrify Ltd.. (7/5/22). "Press Release: Mogrify and Astellas Announce Collaboration to Conduct Research on in vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss". Cambridge & Tokyo....
• [3] Nanna Therapeutics Ltd.. (4/21/20). "Press Release: Astellas Announces Acquisition of Nanna". Tokyo & Cambridge....
• [4] Adaptimmune Therapeutics plc. (1/14/20). "Press Release: Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies". Tokyo, Philadelphia, PA & Oxfordshire....
• [5] Nanna Therapeutics Ltd.. (8/14/18). "Press Release: Addition to Scientific Advisory Board and Company Name Change". Cambridge....
• [6] Astellas Pharma Inc.. (8/10/18). "Press Release: Astellas Announces Acquisition of Quethera". Tokyo & Cambridge....
• [7] Cell and Gene Therapy Catapult, The. (10/5/17). "Press Release: iPSC Line Licensed to Universal Cells to Assist in the Development of Universal Donor Cell line"....
• [8] Bactevo Ltd.. (4/25/17). "Press Release: Bactevo Unveils »TIME« a Novel, Game-changing Medicines Discovery Platform". Cambridge....
• [9] Bactevo Ltd.. (1/25/17). "Press Release: Bactevo Wins Innovate Award". Cambridge....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.